ASP2215
Showing 1 - 25 of 27
Renal Impaired, Gilteritinib, Normal Renal Function Trial in Bulgaria, United States (Gilteritinib)
Active, not recruiting
- Renal Impaired
- +3 more
-
Garden Grove, California
- +3 more
Jul 27, 2022
Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)
Recruiting
- Acute Myeloid Leukemia
- Decitabine and Cedazuridine
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem
Recruiting
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
- gilteritinib
- +3 more
-
Cincinnati, Ohio
- +18 more
Jan 20, 2023
Advanced Solid Tumors, Acute Myeloid Leukemia Trial in United States (Gilteritinib)
Completed
- Advanced Solid Tumors
- Acute Myeloid Leukemia
-
Phoenix, Arizona
- +6 more
Sep 16, 2021
Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia Trial in Japan, Korea, Republic of, Taiwan (gilteritinib,
Active, not recruiting
- Acute Myeloid Leukemia
- FLT3-mutated Acute Myeloid Leukemia
- gilteritinib
- +2 more
-
Anjo, Aichi, Japan
- +54 more
Jan 10, 2023
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Decitabine and Cedazuridine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 19, 2022
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide (gilteritinib, LoDAC (Low Dose
Active, not recruiting
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- gilteritinib
- +3 more
-
Beijing, China
- +47 more
Aug 17, 2022
Hepatic Impairment, Healthy Trial in Miami (ASP2215)
Completed
- Hepatic Impairment
- Healthy
- ASP2215
-
Miami, FloridaSite US10001
Jan 11, 2021
Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)
Withdrawn
- Recurrent Acute Myeloid Leukemia
- Bosutinib Monohydrate
- +6 more
-
Duarte, CaliforniaCity of Hope Meidcal Center
Jun 7, 2022
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in
Recruiting
- Acute Biphenotypic Leukemia
- +13 more
- Cladribine
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 19, 2023
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
-
Los Angeles, California
- +110 more
Jan 26, 2023
Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)
Active, not recruiting
- Leukemia, Acute Myeloid (AML)
- gilteritinib
- +4 more
-
Birmingham, Alabama
- +125 more
Aug 9, 2022
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Canada, Japan, United States (gilteritinib)
Approved for marketing
- Acute Myeloid Leukemia (AML)
- FMS-like Tyrosine Kinase-3 (FLT3) Mutations
-
Los Angeles, California
- +38 more
Apr 18, 2021
Healthy Volunteer Trial in Baltimore (gilteritinib, gilteritinib mini tablet)
Completed
- Healthy Volunteer
- gilteritinib
- gilteritinib mini tablet
-
Baltimore, MarylandEPCU - Parexel
Jun 22, 2020
Acute Myeloid Leukemia (AML) Trial in United States (Venetoclax, Gilteritinib)
Completed
- Acute Myeloid Leukemia (AML)
-
Los Angeles, California
- +10 more
Sep 7, 2021
Acute Myeloid Leukemia Trial in United States (Gilteritinib, Midostaurin, Daunorubicin)
Active, not recruiting
- Acute Myeloid Leukemia
- Gilteritinib
- +3 more
-
Scottsdale, Arizona
- +43 more
Nov 17, 2022
Advanced Solid Tumors, Pharmacokinetics of 14C-labeled Gilteritinib Trial in Cleveland (gilteritinib, 14C-labeled gilteritinib)
Completed
- Advanced Solid Tumors
- Pharmacokinetics of 14C-labeled Gilteritinib
- gilteritinib
- 14C-labeled gilteritinib
-
Cleveland, OhioSite US10001
Mar 13, 2019
Acute Myeloid Leukemia Trial in Canada, Puerto Rico, United States (procedure, drug, behavioral)
Recruiting
- Acute Myeloid Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
- +13 more
-
Birmingham, Alabama
- +187 more
Apr 28, 2022
Acute Myeloid Leukemia Trial in Germany, Italy, United States (Gilteritinib, Voriconazole, Midazolam)
Non-Small-Cell Lung Cancer Trial in Japan (Gilteritinib, Erlotinib)
Terminated
- Non-Small-Cell Lung Cancer
-
Fukuoka Minami-ku, Fukuoka, Japan
- +3 more
Jan 21, 2019
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Worldwide (Gilteritinib, Midostaurin)
Suspended
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome With Excess Blasts-2
-
Adelaide, Australia
- +193 more
Jan 5, 2023
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Australia, Italy, United Kingdom
No longer available
- Acute Myeloid Leukemia (AML)
- FMS-like Tyrosine Kinase-3 (FLT3) Mutations
-
Canberra, Australia
- +5 more
Sep 12, 2018
AML Trial in Los Angeles (ASP2215)
No longer available
- AML
- ASP2215
-
Los Angeles, CaliforniaChildren's Hospital Los Angeles
Apr 13, 2018
Uncontrolled Hypertension, Renal Denervation, Chronic Kidney Disease stage3 Trial in Germany (Renal denervation)
Recruiting
- Uncontrolled Hypertension
- +2 more
- Renal denervation
-
Duesseldorf, Germany
- +3 more
Jan 10, 2022